Overview
Mannose is under investigation for the basic science of IUGR and Pregnancy.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2018/04/13 | Phase 4 | Terminated | Kantonsspital Aarau | ||
2018/01/10 | Phase 2 | Terminated | |||
2015/03/24 | Not Applicable | Terminated |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Mannitole Nicotinate Tablets | 国药准字H21023419 | 化学药品 | 片剂 | 6/24/2020 | |
| Mannitole Nicotinate Tablets | 国药准字H31022605 | 化学药品 | 片剂 | 8/13/2020 | |
| Mannitole Nicotinate Tablets | 国药准字H37023843 | 化学药品 | 片剂 | 2/3/2021 | |
| Mannitole Nicotinate Tablets | 国药准字H36022037 | 化学药品 | 片剂 | 9/22/2021 | |
| Mannitole Nicotinate Tablets | 国药准字H41025003 | 化学药品 | 片剂 | 8/4/2020 | |
| Mannitole Nicotinate Tablets | 国药准字H21023200 | 化学药品 | 片剂 | 5/29/2020 | |
| Mannitole Nicotinate Tablets | 国药准字H42022506 | 化学药品 | 片剂 | 9/7/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.